import React, { Component } from "react";

import "./references.css";

class References extends Component {
  render() {
    return (
      <div className="eng-refs">
        <div className="refs-title">References</div>
        <div className="refs-contnt">
          <br />
          [1] R. Lu et al., “Genomic characterisation and epidemiology of 2019
          novel coronavirus: implications for virus origins and receptor
          binding,” Lancet, vol. 395, no. 10224, pp. 565–574, Feb. 2020, doi:
          10.1016/S0140-6736(20)30251-8. <br />
          [2] P. Zhou et al., “A pneumonia outbreak associated with a new
          coronavirus of probable bat origin,” Nature, vol. 579, no. 7798, pp.
          270–273, Mar. 2020, doi: 10.1038/s41586-020-2012-7. <br />
          [3] Y. He, H. Lu, P. Siddiqui, Y. Zhou, and S. Jiang,
          “Receptor-binding domain of severe acute respiratory syndrome
          coronavirus spike protein contains multiple conformation-dependent
          epitopes that induce highly potent neutralizing antibodies,” J.
          Immunol., vol. 174, no. 8, pp. 4908–4915, Apr. 2005, doi:
          10.4049/jimmunol.174.8.4908. <br />
          [4] S. M.-C. Gobeil et al., “Effect of natural mutations of SARS-CoV-2
          on spike structure, conformation, and antigenicity,” Science, vol.
          373, no. 6555, Aug. 2021, doi: 10.1126/science.abi6226.
          <br />
          [5] S. P. Kaur and V. Gupta, “COVID-19 Vaccine: A comprehensive status
          report,” Virus Res., vol. 288, p. 198114, Oct. 2020, doi:
          10.1016/j.virusres.2020.198114. <br />
          [6] L. Du, Y. He, S. Jiang, and B.-J. Zheng, “Development of subunit
          vaccines against severe acute respiratory syndrome,” Drugs Today ,
          vol. 44, no. 1, pp. 63–73, Jan. 2008, doi:
          10.1358/dot.2008.44.1.1131830. <br />
          [7] M.-P. Deng, Z.-H. Hu, H.-L. Wang, and F. Deng, “Developments of
          subunit and VLP vaccines against influenza A virus,” Virol. Sin., vol.
          27, no. 3, pp. 145–153, Jun. 2012, doi: 10.1007/s12250-012-3241-1.{" "}
          <br />
          [8] M. N. Zahid, M. S. Moosa, S. Perna, and E. B. Buti, “A review on
          COVID-19 vaccines: stages of clinical trials, mode of actions and
          efficacy,” Arab j. basic appl. sci., vol. 28, no. 1, pp. 225–233, Jan.
          2021, doi: 10.1080/25765299.2021.1903144. <br />
          [9] A. Vartak and S. J. Sucheck, “Recent Advances in Subunit Vaccine
          Carriers,” Vaccines (Basel), vol. 4, no. 2, Apr. 2016, doi:
          10.3390/vaccines4020012. <br />
          [10] M. Jeyanathan, S. Afkhami, F. Smaill, M. S. Miller, B. D. Lichty,
          and Z. Xing, “Immunological considerations for COVID-19 vaccine
          strategies,” Nat. Rev. Immunol., vol. 20, no. 10, pp. 615–632, Oct.
          2020, doi: 10.1038/s41577-020-00434-6. <br />
          [11] M. Hansson, P. A. Nygren, and S. Ståhl, “Design and production of
          recombinant subunit vaccines,” Biotechnol. Appl. Biochem., vol. 32,
          no. 2, pp. 95–107, Oct. 2000, doi: 10.1042/ba20000034. <br />
          [12] R. J. W. Sook-San Wong, “Traditional and New Influenza Vaccines,”
          Clin. Microbiol. Rev., vol. 26, no. 3, p. 476, Jul. 2013, doi:
          10.1128/CMR.00097-12. <br />
          [13] M. B. Laurens, “RTS,S/AS01 vaccine (MosquirixTM): an overview,”
          Hum. Vaccin. Immunother., vol. 16, no. 3, p. 480, 2020, doi:
          10.1080/21645515.2019.1669415. <br />
          [14] C. Andersson, “Production and delivery of recombinant subunit
          vaccines,” Bioteknologi, 2000. Accessed: Oct. 24, 2021. [Online].
          Available: https://www.diva-portal.org/smash/get/diva2:8775/FULLTEXT01{" "}
          <br />
          [15] E. Meites, “Human Papillomavirus Vaccination for Adults: Updated
          Recommendations of the Advisory Committee on Immunization Practices,”
          MMWR Morb. Mortal. Wkly. Rep., vol. 68, 2019, doi:
          10.15585/mmwr.mm6832a3. <br />
          [16] P. T. Heath et al., “Safety and Efficacy of NVX-CoV2373 Covid-19
          Vaccine,” N. Engl. J. Med., vol. 385, no. 13, pp. 1172–1183, Sep.
          2021, doi: 10.1056/NEJMoa2107659. <br />
          [17] P. Richmond et al., “Safety and immunogenicity of S-Trimer
          (SCB-2019), a protein subunit vaccine candidate for COVID-19 in
          healthy adults: a phase 1, randomised, double-blind,
          placebo-controlled trial,” Lancet, vol. 397, no. 10275, pp. 682–694,
          Feb. 2021, doi: 10.1016/S0140-6736(21)00241-5.
          <br />
          [18] J. S. Tregoning, K. E. Flight, S. L. Higham, Z. Wang, and B. F.
          Pierce, “Progress of the COVID-19 vaccine effort: viruses, vaccines
          and variants versus efficacy, effectiveness and escape,” Nat. Rev.
          Immunol., vol. 21, no. 10, pp. 626–636, Oct. 2021, doi:
          10.1038/s41577-021-00592-1. <br />
          [19] “Vaxine announces COVID-19 vaccine collaboration with Medytox.”
          https://www.biospectrumasia.com/news/91/16000/vaxine-announces-covid-19-vaccine-collaboration-with-medytox.html
          (accessed Oct. 24, 2021). <br />
          [20] “Medigen Vaccine Biologics Announces Launch of Its COVID-19
          Vaccine MVC-COV1901 Adjuvanted with Dynavax’s CpG 1018 Adjuvant.”
          https://investors.dynavax.com/news-releases/news-release-details/medigen-vaccine-biologics-announces-launch-its-covid-19-vaccine
          (accessed Oct. 24, 2021). <br />
          [21] “Adjuvants: Introduction.”
          https://www.immunology.org/es/public-information/bitesized-immunology/vaccines-and-therapeutics/adyuvantes-introducci%C3%B3n
          (accessed Oct. 24, 2021). <br />
          [22] S. Awate, L. A. Babiuk, and G. Mutwiri, “Mechanisms of action of
          adjuvants,” Front. Immunol., vol. 4, p. 114, May 2013, doi:
          10.3389/fimmu.2013.00114. <br />
          [23] H. F. J. Savelkoul, V. A. Ferro, M. M. Strioga, and V. E. J. C.
          Schijns, “Choice and Design of Adjuvants for Parenteral and Mucosal
          Vaccines,” Vaccines (Basel), vol. 3, no. 1, pp. 148–171, Mar. 2015,
          doi: 10.3390/vaccines3010148.
          <br />
          [24] T. Aoshi, “Modes of Action for Mucosal Vaccine Adjuvants,” Viral
          Immunol., vol. 30, no. 6, pp. 463–470, Apr. 2017, doi:
          10.1089/vim.2017.0026. <br />
          [25] R.-M. Hernández-Ramos, I. Castillo-Maldonado, M.-A.
          Rivera-Guillén, A. Ramírez-Moreno, L.-B. Serrano-Gallardo, and D.
          Pedroza-Escobar, “Plant Phenolics and Lectins as Vaccine Adjuvants,”
          Curr. Pharm. Biotechnol., vol. 20, no. 15, pp. 1236–1243, Nov. 2019,
          Accessed: Oct. 24, 2021. [Online]. Available:
          https://www.eurekaselect.com/173520/article <br />
          [26] Y. He, H. Lu, P. Siddiqui, Y. Zhou, and S. Jiang,
          “Receptor-binding domain of severe acute respiratory syndrome
          coronavirus spike protein contains multiple conformation-dependent
          epitopes that induce highly potent neutralizing antibodies,” J.
          Immunol., vol. 174, no. 8, pp. 4908–4915, Apr. 2005, doi:
          10.4049/jimmunol.174.8.4908. <br />
          [27] Y. Yang and L. Du, “SARS-CoV-2 spike protein: a key target for
          eliciting persistent neutralizing antibodies,” Signal transduction and
          targeted therapy, vol. 6, no. 1. p. 95, Feb. 26, 2021. doi:
          10.1038/s41392-021-00523-5. <br />
          [28] S. Su, L. Du, and S. Jiang, “Learning from the past: development
          of safe and effective COVID-19 vaccines,” Nat. Rev. Microbiol., vol.
          19, no. 3, pp. 211–219, Oct. 2020, doi: 10.1038/s41579-020-00462-y.{" "}
          <br />
          [29] D. F. Robbiani et al., “Convergent antibody responses to
          SARS-CoV-2 in convalescent individuals,” Nature, vol. 584, no. 7821,
          pp. 437–442, Aug. 2020, doi: 10.1038/s41586-020-2456-9. <br />
          [30] T. N. Starr et al., “Antibodies to the SARS-CoV-2
          receptor-binding domain that maximize breadth and resistance to viral
          escape,” bioRxiv. doi: 10.1101/2021.04.06.438709. <br />
          [31] “Farmacovigilancia de vacunas para COVID-19 - Catálogo.”
          https://covid-19pharmacovigilance.paho.org/ (accessed Oct. 24, 2021).{" "}
          <br />
          [32] “KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers.”
          https://clinicaltrials.gov/ct2/show/NCT04473690 (accessed Oct. 24,
          2021). <br />
          [33] S. Kwon, Y. Jung, and D. Lim, “Proteomic analysis of heat-stable
          proteins in Escherichia coli,” BMB Rep., vol. 41, no. 2, pp. 108–111,
          Feb. 2008, doi: 10.5483/bmbrep.2008.41.2.108. <br />
          [34] H. Huang, J. Liu, and A. de Marco, “Induced fit of passenger
          proteins fused to Archaea maltose binding proteins,” Biochem. Biophys.
          Res. Commun., vol. 344, no. 1, pp. 25–29, May 2006, doi:
          10.1016/j.bbrc.2006.03.151. <br />
          [35] J. D. Fox, K. M. Routzahn, M. H. Bucher, and D. S. Waugh,
          “Maltodextrin-binding proteins from diverse bacteria and archaea are
          potent solubility enhancers,” FEBS Lett., vol. 537, no. 1–3, pp.
          53–57, Feb. 2003, doi: 10.1016/s0014-5793(03)00070-x. <br />
          [36] J. M. Luke, A. E. Carnes, P. Sun, C. P. Hodgson, D. S. Waugh, and
          J. A. Williams, “Thermostable tag (TST) protein expression system:
          engineering thermotolerant recombinant proteins and vaccines,” J.
          Biotechnol., vol. 151, no. 3, pp. 242–250, Feb. 2011, doi:
          10.1016/j.jbiotec.2010.12.011. <br />
          [37] A. Thapa et al., “Purification of inclusion body-forming peptides
          and proteins in soluble form by fusion to Escherichia coli
          thermostable proteins,” Biotechniques, vol. 44, no. 6, pp. 787–796,
          May 2008, doi: 10.2144/000112728. <br />
          [38] J. Westfall et al., “Thermal stability and epitope integrity of a
          lyophilized ricin toxin subunit vaccine,” Vaccine, vol. 36, no. 40,
          pp. 5967–5976, Sep. 2018, doi: 10.1016/j.vaccine.2018.08.059. <br />
          [39] A. de Marco, E. Casatta, S. Savaresi, and A. Geerlof,
          “Recombinant proteins fused to thermostable partners can be purified
          by heat incubation,” J. Biotechnol., vol. 107, no. 2, pp. 125–133,
          Jan. 2004, doi: 10.1016/j.jbiotec.2003.10.008. <br />
          [40] A. G. Evdokimov, D. E. Anderson, K. M. Routzahn, and D. S. Waugh,
          “Structural basis for oligosaccharide recognition by Pyrococcus
          furiosus maltodextrin-binding protein,” J. Mol. Biol., vol. 305, no.
          4, pp. 891–904, Jan. 2001, doi: 10.1006/jmbi.2000.4202. <br />
          [41] S. A. Walper et al., “Thermostable single domain antibody-maltose
          binding protein fusion for Bacillus anthracis spore protein BclA
          detection,” Anal. Biochem., vol. 447, pp. 64–73, Feb. 2014, doi:
          10.1016/j.ab.2013.10.031. <br />
          [42] A. Pusztai and G. Grant, “Assessment of lectin inactivation by
          heat and digestion,” Methods Mol. Med., vol. 9, pp. 505–514, 1998,
          doi: 10.1385/0-89603-396-1:505. <br />
          [43] T. F. B. Van Der Poel, J. Blonk, D. J. Van Zuilichem, and M. G.
          Van Oort, “Thermal inactivation of lectins and trypsin inhibitor
          activity during steam processing of dry beans (Phaseolus vulgaris) and
          effects on protein quality,” J. Sci. Food Agric., vol. 53, no. 2, pp.
          215–228, 1990, doi: 10.1002/jsfa.2740530209. <br />
          [44] E. M. Aregheore, H. P. S. Makkar, and K. Becker, “Assessment of
          lectin activity in a toxic and a non-toxic variety ofJatropha curcas
          using latex agglutination and haemagglutination methods and
          inactivation of lectin by heat treatments,” Journal of the Science of
          Food and Agriculture, vol. 77, no. 3. pp. 349–352, 1998. doi:
          10.1002/(sici)1097-0010(199807)77:3
          {/* <349::aid-jsfa49> */}3.0.co;2-a. <br />
          [45] E. C. Lavelle, G. Grant, A. Pusztai, U. Pfüller, and D. T.
          O’Hagan, “The identification of plant lectins with mucosal adjuvant
          activity,” Immunology, vol. 102, no. 1, pp. 77–86, Jan. 2001, doi:
          10.1046/j.1365-2567.2001.01157.x. <br />
          [46] K. Witthohn and H. Lentzen, “Recombinant Mistletoe Lectin and use
          Thereof as an Adjuvant,” 20140220076:A1, Aug. 07, 2014 Accessed: Oct.
          24, 2021. [Online]. Available:
          https://patentimages.storage.googleapis.com/75/1c/ea/e6812c20c8133b/US20140220076A1.pdf
          <br />
          [47] A. Firsov et al., “Expression and Immunogenicity of M2e Peptide
          of Avian Influenza Virus H5N1 Fused to Ricin Toxin B Chain Produced in
          Duckweed Plants,” Front Chem, vol. 6, p. 22, Feb. 2018, doi:
          10.3389/fchem.2018.00022. <br />
          [48] M. Wang, Z. Gao, Z. Zhang, L. Pan, and Y. Zhang, “Roles of M
          cells in infection and mucosal vaccines,” Hum. Vaccin. Immunother.,
          vol. 10, no. 12, pp. 3544–3551, 2014, doi: 10.4161/hv.36174. <br />
          [49] E. Rutenber, M. Ready, and J. D. Robertus, “Structure and
          evolution of ricin B chain,” Nature, vol. 326, no. 6113, pp. 624–626,
          1987, doi: 10.1038/326624a0. <br />
          [50] B. Chazaud, M. P. Muriel, J. Wantyghem, M. Aubery, and M.
          Decastel, “Ricin toxicity and intracellular routing in tumoral HT-29
          cells. II. Differential ricin toxicity from the apical and basolateral
          surfaces of differentiated HT-29 cells,” Exp. Cell Res., vol. 221, no.
          1, pp. 214–220, Nov. 1995, doi: 10.1006/excr.1995.1369. <br />
          [51] A. Singh et al., “Expression of rabies glycoprotein and ricin
          toxin B chain (RGP-RTB) fusion protein in tomato hairy roots: a step
          towards oral vaccination for rabies,” Mol. Biotechnol., vol. 57, no.
          4, pp. 359–370, Apr. 2015, doi: 10.1007/s12033-014-9829-y. <br />
          [52] N.-W. Choi, M. K. Estes, and W. H. R. Langridge, “Mucosal
          immunization with a ricin toxin B subunit-rotavirus NSP4 fusion
          protein stimulates a Th1 lymphocyte response,” J. Biotechnol., vol.
          121, no. 2, pp. 272–283, Jan. 2006, doi:
          10.1016/j.jbiotec.2005.07.024. <br />
          [53] A. J. Donayre-Torres, E. Esquivel-Soto, M. de L.
          Gutiérrez-Xicoténcatl, F. R. Esquivel-Guadarrama, and M. A. Gómez-Lim,
          “Production and purification of immunologically active core protein
          p24 from HIV-1 fused to ricin toxin B subunit in E. coli,” Virol. J.,
          vol. 6, p. 17, Feb. 2009, doi: 10.1186/1743-422X-6-17. <br />
          [54] F. Medina-Bolivar et al., “A non-toxic lectin for antigen
          delivery of plant-based mucosal vaccines,” Vaccine, vol. 21, no. 9–10,
          pp. 997–1005, Feb. 2003, doi: 10.1016/s0264-410x(02)00551-0. <br />
          [55] G. L. Rosano and E. A. Ceccarelli, “Recombinant protein
          expression in Escherichia coli: advances and challenges,” Front.
          Microbiol., vol. 0, 2014, doi: 10.3389/fmicb.2014.00172. <br />
          [56] V. P. Reddy Chichili, V. Kumar, and J. Sivaraman, “Linkers in the
          structural biology of protein-protein interactions,” Protein Sci.,
          vol. 22, no. 2, pp. 153–167, Feb. 2013, doi: 10.1002/pro.2206. <br />
          [57] P. Argos, “An investigation of oligopeptides linking domains in
          protein tertiary structures and possible candidates for general gene
          fusion,” J. Mol. Biol., vol. 211, no. 4, pp. 943–958, Feb. 1990, doi:
          10.1016/0022-2836(90)90085-Z. <br />
          [58] X. Chen, J. L. Zaro, and W.-C. Shen, “Fusion protein linkers:
          property, design and functionality,” Adv. Drug Deliv. Rev., vol. 65,
          no. 10, pp. 1357–1369, Oct. 2013, doi: 10.1016/j.addr.2012.09.039.
          <br />
          [59] M. Saadi, A. Karkhah, and H. R. Nouri, “Development of a
          multi-epitope peptide vaccine inducing robust T cell responses against
          brucellosis using immunoinformatics based approaches,” Infect. Genet.
          Evol., vol. 51, pp. 227–234, Jul. 2017, doi:
          10.1016/j.meegid.2017.04.009. <br />
          [60] T. Kar et al., “A candidate multi-epitope vaccine against
          SARS-CoV-2,” Sci. Rep., vol. 10, no. 1, p. 10895, Jul. 2020, doi:
          10.1038/s41598-020-67749-1. <br />
          [61] R. Donev, Protein Structure and Diseases. Academic Press, 2011.{" "}
          [Online]. Available:
          https://books.google.com/books/about/Protein_Structure_and_Diseases.html?hl=&id=g2GNF6faZhkC
          <br />
          [62] V. B. Chen et al., “MolProbity: all-atom structure validation for
          macromolecular crystallography,” Acta Crystallogr. D Biol.
          Crystallogr., vol. 66, no. Pt 1, pp. 12–21, Jan. 2010, doi:
          10.1107/S0907444909042073. <br />
          [63] J. Ko, H. Park, L. Heo, and C. Seok, “GalaxyWEB server for
          protein structure prediction and refinement,” Nucleic Acids Res., vol.
          40, no. Web Server issue, pp. W294–7, Jul. 2012, doi:
          10.1093/nar/gks493. <br />
          [64] A. N. Ilinskaya and M. A. Dobrovolskaia, “Understanding the
          immunogenicity and antigenicity of nanomaterials: Past, present and
          future,” Toxicol. Appl. Pharmacol., vol. 299, pp. 70–77, May 2016,
          doi: 10.1016/j.taap.2016.01.005. <br />
          [65] W. R. Martin and F. Cheng, “A rational design of a multi-epitope
          vaccine against SARS-CoV-2 which accounts for the glycan shield of the
          spike glycoprotein,” J. Biomol. Struct. Dyn., pp. 1–15, Mar. 2021,
          doi: 10.1080/07391102.2021.1894986. <br />
          [66] M. V. Larsen, C. Lundegaard, K. Lamberth, S. Buus, O. Lund, and
          M. Nielsen, “Large-scale validation of methods for cytotoxic
          T-lymphocyte epitope prediction,” BMC Bioinformatics, vol. 8, p. 424,
          Oct. 2007, doi: 10.1186/1471-2105-8-424. <br />
          [67] K. K. Jensen et al., “Improved methods for predicting peptide
          binding affinity to MHC class II molecules,” Immunology, vol. 154, no.
          3, pp. 394–406, Jul. 2018, doi: 10.1111/imm.12889. <br />
          [68] W. Fleri et al., “The Immune Epitope Database and Analysis
          Resource in Epitope Discovery and Synthetic Vaccine Design,” Front.
          Immunol., vol. 0, 2017, doi: 10.3389/fimmu.2017.00278.
          <br />
          [69] Z. Chen and E. John Wherry, “T cell responses in patients with
          COVID-19,” Nat. Rev. Immunol., vol. 20, no. 9, pp. 529–536, Sep. 2020,
          doi: 10.1038/s41577-020-0402-6. <br />
          [70] I. A. Doytchinova and D. R. Flower, “VaxiJen: a server for
          prediction of protective antigens, tumour antigens and subunit
          vaccines,” BMC Bioinformatics, vol. 8, no. 1, pp. 1–7, Jan. 2007, doi:
          10.1186/1471-2105-8-4. <br />
          [71] S. Kumar, V. K. Maurya, A. K. Prasad, M. L. B. Bhatt, and S. K.
          Saxena, “Structural, glycosylation and antigenic variation between
          2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV),”
          Virusdisease, vol. 31, no. 1, pp. 13–21, Mar. 2020, doi:
          10.1007/s13337-020-00571-5. <br />
          [72] F. Pucci, J. M. Kwasigroch, and M. Rooman, “SCooP: an accurate
          and fast predictor of protein stability curves as a function of
          temperature,” Bioinformatics, vol. 33, no. 21, pp. 3415–3422, Nov.
          2017, doi: 10.1093/bioinformatics/btx417.
        </div>
      </div>
    );
  }
}

export default References;
